• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GoHealth Reports Second Quarter 2023 Results

    8/10/23 6:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance
    Get the next $GOCO alert in real time by email

    CHICAGO, Aug. 10, 2023 /PRNewswire/ -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and six months ended June 30, 2023.

    GoHealth, Inc. (PRNewsfoto/GoHealth, Inc.)

    • Second quarter 2023 net revenues of $142.8 million, a decrease of $15.9 million compared to $158.7 million in the prior year period. YTD 2023 net revenues of $325.9 million, a decrease of $103.3 million compared to $429.2 million in the prior year period.
    • Second quarter 2023 Submissions of 162,837, a 5% improvement compared to 154,893 Submissions in the prior year period. Demand for our services remains robust, and we continue to invest in technology to enhance our value proposition.
    • Second quarter 2023 net loss of $70.2 million, an improvement of $43.5 million compared to $113.8 million in the prior year period. YTD 2023 net loss of $92.8 million, an improvement of $58.2 million compared to $151.0 million in the prior year period.
    • Second quarter 2023 Adjusted EBITDA1 of $0.8 million, an improvement of $32.5 million compared to negative $31.7 million in the prior year period. YTD 2023 Adjusted EBITDA1 of $29.6 million, an improvement of $50.2 million compared to negative $20.7 million in the prior year period.
    • Second quarter 2023 Trailing Twelve Months positive cash flow from operations of $85.9 million, an improvement of $346.2 million compared to a use of cash of $260.4 million in the prior year period.

    Special Committee Rejects $20.00 per share Unsolicited Non-Binding Proposal



    After careful review and consideration with its independent financial and legal advisors, the Special Committee of the GoHealth Board of Directors (the "Special Committee") has informed the Company that it has rejected the previously announced $20.00 per share unsolicited, non-binding proposal received on May 18, 2023 (the "Proposal") from its two largest stockholders to acquire all of the outstanding Class A Common Stock and LLC interests that these stockholders do not already own.  The Special Committee unanimously concluded that the Proposal significantly undervalues the Company and is not in the best interests of GoHealth or its stockholders.



    The Special Committee provided the following statement: "We believe the Proposal undervalues GoHealth and fails to recognize the strength of our business today as well as our compelling future prospects. We have confidence in the leadership team's ability to execute the Company's long range strategic plan."



    Vijay Kotte, CEO, GoHealth, added, "Building off a strong finish to 2022 and first half of 2023, we continue to successfully execute our overall strategy and launched several key initiatives early this year that are already delivering results and support our overall objectives to manage the business efficiently and effectively, and drive cash flow, increased revenue, and profitability. We are pleased with the significant progress we have made on our Encompass strategy thus far and anticipate accelerated improvement through the remainder of the year."



    Updating Full Year 2023 Guidance



    The Company updates its full year 2023 outlook and expects total net revenue3 of $800 - $850 million and Adjusted EBITDA1 of $120 - $140 million, both excluding non-Encompass BPO Services.2 These guidance updates reflect increases to the lower bounds previously communicated for total net revenue and Adjusted EBITDA1 ranges. The Company also expects positive cash flow from operations of $75 - $115 million.



    "At GoHealth, we remain steadfastly committed to enhancing the consumer experience, which has been a driving force behind our shift to Encompass," stated Vijay Kotte, CEO of GoHealth. "Encompass offers a standardized workflow, driving a consistent consumer experience that results in a higher quality and greater cost efficiency for us. As we embark on our next stage of growth, I am proud to share that GoHealth has been making continuous strides by harnessing the power of our enhanced technology tools, which have yielded early efficiency returns and an unparalleled consumer experience."



    "As we report our latest financial results, I am pleased to announce that we are raising the floor on our guidance, reflecting the robust performance and confidence in our future prospects. Our revised expectations for total net revenue and adjusted EBITDA signify our commitment to sustained growth and our dedication to delivering value to our shareholders. We remain focused on driving innovation, operational excellence, and market leadership, and we look forward to building on this momentum in the coming quarters," stated Jason Schulz, CFO of GoHealth.

    The Company made the strategic decision to exit its non-Encompass BPO Services2 to focus on its core business. The exit was completed in the second quarter of 2023. For the three and six months ended June 30, 2023, non-Encompass BPO Services2 contributed $2.5 million and $9.3 million of net revenue with a gross margin of $0.3 million and $1.7 million, respectively. For the three and six months ended June 30, 2023, net revenue excluding non-Encompass BPO Services2 revenue of $2.5 million and $9.3 million was $140.3 million and $316.6 million, respectively, and Adjusted EBITDA1 excluding non-Encompass BPO Services3 gross margin of $0.3 million and $1.7 million was $0.5 million and $27.9 million, respectively.3

    During the first quarter of 2023, the Company reorganized its operations from four operating and reportable segments to one operating and reportable segment. The change reflects how the Company's chief operating decision maker ("CODM") evaluates the Company's operating and financial performance on a consolidated basis and is consistent with changes made to the Company's internal reporting structure. Additionally, the single operating segment aligns with the Company's shift in focus towards Medicare products. Operating segments are identified as components of an enterprise about which separate discrete financial information is available and reviewed regularly by the CODM. The Company's CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company's performance. All prior period comparative segment information was recast to reflect the current single operating segment in accordance with Accounting Standards Codification 280, Segment Reporting.

    Conference Call Details

    The Company will host a conference call today, Thursday, August 10, 2023 at 8:00 a.m. (ET) to discuss its financial results.  Participants can pre-register for the conference call at the following link: https://edge.media-server.com/mmc/p/2iudd3hc. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website. A replay of the call will be available via webcast on GoHealth's Investor Relations website for on-demand listening shortly after the completion of the call.

    About GoHealth, Inc.

    As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for consumers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and health plan partner that is right for them. GoHealth has enrolled millions of people in Medicare plans and individual and family plans. For more information, visit https://www.gohealth.com.

    Investor Relations:

    John Shave

    [email protected]

    Media Relations:

    [email protected]

    (1)

    Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

    (2)

    Non-Encompass BPO Services are those services in which we dedicate certain agents to specific health plan partners and agencies, outside of the Encompass Solution.

    (3)

    Net revenue excluding non-Encompass BPO Services revenue and Adjusted EBITDA excluding non-Encompass BPO Services gross margin are non-GAAP measures. For a reconciliation to the most comparable GAAP measure, please see table provided below.

    Forward-Looking Statements

    This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended ("the Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("the Exchange Act"). All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding our expected growth, level of cash flow, future capital expenditures and debt service obligations are forward-looking statements.

    In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "aim," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "likely," "future," or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

    These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including, but are not limited to, the following: the marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws, regulations and guidelines; our operating results have been, and may continue to be, adversely impacted by factors that impact our estimate of LTV; our gradual expansion of the Encompass Solution may not be as successful as we expect; our business may be harmed if we lose our relationships with health plans or if our relationships with health plans change; health plans may reduce the commissions paid to us and change their underwriting practices in ways that reduce the number of, or impact the renewal or approval rates of, insurance policies sold through our platform; our management identified a material weakness in our internal controls over financial reporting, and we may be unable to develop, implement and maintain appropriate controls in future periods, which may lead to errors or omissions in our financial statements; we currently depend on a small group of health plans for a substantial portion of our revenue; information technology system failures could interrupt our operations; factors that impact our estimate of LTV (as defined below); we may lose key employees or fail to attract qualified employees; our failure to grow our customer base or retain our existing customers; we may not realize the benefits we expect from our strategic cash flow optimization and other cash management initiatives; our ability to sell Medicare-related health insurance plans is largely dependent on our licensed health insurance agents; operating and growing our business may require additional capital; and the Founders and Centerbridge have significant influence over us, including control over decisions that require the approval of stockholders.

    The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in our 2022 Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the first fiscal quarter ended March 31, 2023, our forthcoming Quarterly Report on Form 10-Q for the second quarter ended June 30, 2023, and our other filings with the Securities and Exchange Commission. If one or more events related to these or other risks or uncertainties materialize, or our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. Many of the important factors that will determine these results are beyond our ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

    Use of Non-GAAP Financial Measures and Key Performance Indicators

    In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA; Adjusted EBITDA; Adjusted EBITDA margin; Sales per Submission; Cost per Submission and Adjusted Gross Margin per Submission. Adjusted EBITDA is the primary financial performance measure used by management to evaluate the business and monitor its results of operations. Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission are key operating metrics used by management to understand the Company's underlying financial performance and trends.

    Additional non-GAAP financial measures, including net revenue excluding the Lookback Adjustments, Adjusted EBITDA excluding the Lookback Adjustments, net revenue excluding both the non-Encompass BPO Services revenue and the Lookback Adjustments and Adjusted EBITDA excluding both the non-Encompass BPO Services gross margin and the Lookback Adjustments, are also discussed in this press release. The Lookback Adjustments are revenue adjustments that represent changes in estimates relating to performance obligations satisfied in prior periods and relate to the fiscal years 2021 and prior.

    Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items summarized below in this press release. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues. Sales per Submission represents Medicare Revenue per Submission as further adjusted for certain items summarized below in this press release. Cost per Submission represents Operating Expense per Submission as further adjusted for certain items summarized below in this press release. Adjusted Gross Margin represents Sales per Submission less Cost per Submission.

    We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. Adjusted EBITDA is used as a basis for certain compensation programs sponsored by the Company. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

    The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA, Adjusted EBITDA, net revenue excluding the Lookback Adjustments, Adjusted EBITDA excluding the Lookback Adjustments, net revenue excluding both the non-Encompass BPO Services revenue and the Lookback Adjustments, Adjusted EBITDA excluding both the non-Encompass BPO Services gross margin and the Lookback Adjustments, Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission to its most directly comparable GAAP financial measure, are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

    The Company is unable to provide a full reconciliation of guidance for Adjusted EBITDA without unreasonable effort because it is not possible to predict certain adjustment items with a reasonable degree of certainty since they are not yet known or quantifiable, and do not relate to the Company's routine activities. This information is dependent upon future events, which may be outside of the Company's control and could have a significant impact on its GAAP financial results for fiscal 2023.

    Glossary

    • "Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for certain items summarized below in this press release.
    • "Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.
    • "Adjusted Gross Margin per Submission" refers to Sales per Submission less Cost per Submission.
    • "Cost of Submission" refers to the aggregate cost to convert prospects into Submissions during a particular period. Cost of Submission is comprised of revenue share, marketing and advertising expenses, and customer care and enrollment expenses, excluding share-based compensation expense and such expenses related to non-Encompass BPO Services.
    • "Cost per Submission" refers to (x) the aggregate cost to convert prospects into Submissions for a particular period (comprised of revenue share, marketing and advertising expenses, and customer care and enrollment expenses, excluding share-based compensation expense and such expenses related to non-Encompass BPO Services) divided by (y) either (i) a completed application with our licensed agent that is submitted to the insurance health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our non-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass marketplace during the indicated period.
    • "EBITDA" represents net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense.
    • "Gross margin" refers to net revenue divided by revenue share, marketing and advertising expenses and customer care and enrollment expenses.
    • "LTV" refers to the Lifetime Value of Commissions, which we define as aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan mix and expected policy persistency with applied constraints.
    • "Non-Encompass BPO Services" refer to programs in which GoHealth-employed agents are dedicated to certain health plans and agencies we partner with outside of the Encompass model.
    • "Sales per Submission" refers to (x) the combination sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the number of Submissions for such period.
    • "Sales/Cost of Submission" refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) Encompass revenue, and (iii) partner marketing and enrollment services, divided by (y) the aggregate cost to convert prospects into Submissions (comprised of revenue share, marketing and advertising expenses, and customer care and enrollment expenses, excluding share-based compensation expense) for such period. Sales and Cost of Submission exclude amounts related to non-Encompass BPO Services.
    • "Submission" refers to either (i) a completed application with our licensed agent that is submitted to the insurance health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our non-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass marketplace during the indicated period.

    The following tables set forth the components of our results of operations for the periods indicated (unaudited):





    Three months ended

    Jun. 30, 2023



    Three months ended

    Jun. 30, 2022









    (in thousands, except percentages and per share amounts)



    Dollars



    % of Net

    Revenues



    Dollars



    % of Net

    Revenues



    $ Change



    % Change

    Net revenues



    $  142,779



    100.0 %



    $    158,654



    100.0 %



    $   (15,875)



    (10.0) %

    Operating expenses:

























    Revenue share



    36,422



    25.5 %



    51,074



    32.2 %



    (14,652)



    (28.7) %

    Marketing and advertising



    39,269



    27.5 %



    44,714



    28.2 %



    (5,445)



    (12.2) %

    Customer care and enrollment



    45,536



    31.9 %



    66,542



    41.9 %



    (21,006)



    (31.6) %

    Technology



    10,511



    7.4 %



    10,749



    6.8 %



    (238)



    (2.2) %

    General and administrative



    37,855



    26.5 %



    38,106



    24.0 %



    (251)



    (0.7) %

    Amortization of intangible assets



    23,515



    16.5 %



    23,515



    14.8 %



    —



    — %

    Operating lease impairment charges



    2,687



    1.9 %



    24,995



    15.8 %



    (22,308)



    (89.2) %

    Total operating expenses



    195,795



    137.1 %



    259,695



    163.7 %



    (63,900)



    (24.6) %

    Income (loss) from operations



    (53,016)



    (37.1) %



    (101,041)



    (63.7) %



    48,025



    (47.5) %

    Interest expense



    17,265



    12.1 %



    12,724



    8.0 %



    4,541



    35.7 %

    Other (income) expense, net



    21



    — %



    (13)



    — %



    34



    (261.5) %

    Income (loss) before income taxes



    (70,302)



    (49.2) %



    (113,752)



    (71.7) %



    43,450



    (38.2) %

    Income tax (benefit) expense



    (73)



    (0.1) %



    —



    — %



    (73)



    N/M

    Net income (loss)



    $  (70,229)



    (49.2) %



    $   (113,752)



    (71.7) %



    $    43,523



    (38.3) %

    Net income (loss) attributable to non-controlling interests



    (41,287)



    (28.9) %



    (69,933)



    (44.1) %



    28,646



    (41.0) %

    Net income (loss) attributable to GoHealth, Inc.



    $  (28,942)



    (20.3) %



    $     (43,819)



    (27.6) %



    $    14,877



    (34.0) %

    Net income (loss) per share:

























    Net income (loss) per share of Class A common stock —

    basic and diluted



    $      (3.27)







    $         (5.28)













    Weighted-average shares of Class A common stock

    outstanding — basic and diluted



    9,122







    8,296













    Non-GAAP financial measures:

























    EBITDA



    $  (26,669)







    $     (74,617)













    Adjusted EBITDA



    $        788







    $     (31,741)













    Adjusted EBITDA margin



    0.6 %







    (20.0) %













    _________________________

    N/M = Not meaningful

     





    Six months ended

    Jun. 30, 2023



    Six months ended

    Jun. 30, 2022









    (in thousands, except percentages and per share amounts)



    Dollars



    % of Net

    Revenues



    Dollars



    % of Net

    Revenues



    $ Change



    % Change

    Net revenues



    $  325,937



    100.0 %



    $   429,247



    100.0 %



    $ (103,310)



    (24.1) %

    Operating expenses:

























    Revenue share



    81,884



    25.1 %



    118,997



    27.7 %



    (37,113)



    (31.2) %

    Marketing and advertising



    85,012



    26.1 %



    128,747



    30.0 %



    (43,735)



    (34.0) %

    Customer care and enrollment



    87,563



    26.9 %



    144,997



    33.8 %



    (57,434)



    (39.6) %

    Technology



    20,054



    6.2 %



    23,508



    5.5 %



    (3,454)



    (14.7) %

    General and administrative



    60,473



    18.6 %



    67,323



    15.7 %



    (6,850)



    (10.2) %

    Amortization of intangible assets



    47,029



    14.4 %



    47,029



    11.0 %



    —



    — %

    Operating lease impairment charges



    2,687



    0.8 %



    24,995



    5.8 %



    (22,308)



    (89.2) %

    Total operating expenses



    384,702



    118.0 %



    555,596



    129.4 %



    (170,894)



    (30.8) %

    Income (loss) from operations



    (58,765)



    (18.0) %



    (126,349)



    (29.4) %



    67,584



    (53.5) %

    Interest expense



    34,156



    10.5 %



    24,122



    5.6 %



    10,034



    41.6 %

    Other (income) expense, net



    (32)



    — %



    50



    — %



    (82)



    (164.0) %

    Income (loss) before income taxes



    (92,889)



    (28.5) %



    (150,521)



    (35.1) %



    57,632



    (38.3) %

    Income tax (benefit) expense



    (117)



    — %



    472



    0.1 %



    (589)



    (124.8) %

    Net income (loss)



    $  (92,772)



    (28.5) %



    $  (150,993)



    (35.2) %



    $    58,221



    (38.6) %

    Net income (loss) attributable to non-controlling interests



    (54,651)



    (16.8) %



    (93,691)



    (21.8) %



    39,040



    (41.7) %

    Net income (loss) attributable to GoHealth, Inc.



    $  (38,121)



    (11.7) %



    $    (57,302)



    (13.3) %



    $    19,181



    (33.5) %

    Net income (loss) per share:

























    Net income (loss) per share of Class A common stock —

    basic and diluted



    $      (4.41)







    $        (7.14)













    Weighted-average shares of Class A common stock

    outstanding — basic and diluted



    9,044







    8,023













    Non-GAAP financial measures:

























    EBITDA



    $    (6,098)







    $    (74,040)













    Adjusted EBITDA



    $   29,566







    $    (20,668)













    Adjusted EBITDA margin



    9.1 %







    (4.8) %













    _________________________

    NM = Not meaningful

     

    The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):





    Three months ended Jun. 30,



    Six months ended Jun. 30,

    (in thousands)



    2023



    2022



    2023



    2022

    Net revenues



    $        142,779



    $        158,654



    $        325,937



    $        429,247

    Net income (loss)



    (70,229)



    (113,752)



    (92,772)



    (150,993)

    Interest expense



    17,265



    12,724



    34,156



    24,122

    Income tax expense (benefit)



    (73)



    —



    (117)



    472

    Depreciation and amortization expense



    26,368



    26,411



    52,635



    52,359

    EBITDA



    (26,669)



    (74,617)



    (6,098)



    (74,040)

    Share-based compensation expense1



    10,120



    14,257



    16,704



    19,412

    Legal fees2



    12,730



    —



    14,353



    —

    Operating lease impairment charges3



    2,687



    24,995



    2,687



    24,995

    Severance costs4



    1,920



    3,624



    1,920



    5,015

    Professional services5



    —



    —



    —



    3,950

    Adjusted EBITDA



    $               788



    $         (31,741)



    $          29,566



    $         (20,668)

    Adjusted EBITDA margin



    0.6 %



    (20.0) %



    9.1 %



    (4.8) %

    _________________________

    (1)

    Represents non-cash share-based compensation expense relating to equity awards, as well share-based compensation expense relating to liability classified awards that will be settled in cash

    (2)

    Represents non-routine legal fees and accruals unrelated to our core operations.

    (3)

    Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values.

    (4)

    Represents costs associated with the termination of executive employment and associated fees unrelated to restructuring activities.

    (5)

    Represents costs associated with non-recurring consulting fees and other professional services.

     

    The following table summarizes net revenues and Adjusted EBITDA excluding the Lookback Adjustments and non-Encompass BPO Services for the periods indicated (unaudited):





    Three months ended Jun. 30,



    Six months ended Jun. 30,

    (in thousands)



    2023



    2022



    2023



    2022

    Net revenues



    $       142,779



    $       158,654



    $       325,937



    $       429,247

    Lookback Adjustments reported during the indicated periods1



    —



    3,162



    —



    5,480

    Net revenue excluding Lookback Adjustments



    142,779



    161,816



    325,937



    434,727

    Exit of non-Encompass BPO Services



    (2,528)



    (23,119)



    (9,322)



    (58,056)

    Net revenues excluding Lookback Adjustments and non-

    Encompass BPO Services



    140,251



    138,697



    316,615



    376,671



















    Adjusted EBITDA



    $              788



    $       (31,741)



    $         29,566



    $       (20,668)

    Lookback Adjustments reported during the indicated periods1



    —



    2,300



    —



    3,961

    Adjusted EBITDA excluding Lookback Adjustments



    788



    (29,441)



    29,566



    (16,707)

    Exit of non-Encompass BPO Services



    (265)



    (3,619)



    (1,667)



    (10,809)

    Adjusted EBITDA excluding Lookback Adjustments and non-

    Encompass BPO Services



    $              523



    $       (33,060)



    $         27,899



    $       (27,516)

     Adjusted EBITDA margin excluding Lookback Adjustments and

    non-Encompass BPO Services



    0.4 %



    (23.8) %



    8.8 %



    (7.3) %

    _________________________

    (1)

    Excludes the impact of Lookback Adjustments on non-Encompass BPO Services





















     

    The table below depicts the disaggregation of revenue and is consistent with how the Company evaluates its financial performance (unaudited):





    Three months ended Jun. 30,



    Six months ended Jun. 30,

    (in thousands)



    2023



    2022



    2023



    2022

    Medicare Revenue

















    Agency Revenue

















    Commission Revenue1



    $           87,403



    $         109,027



    $         184,934



    $         300,720

    Partner Marketing and Other Revenue



    23,195



    21,379



    50,319



    55,406

    Total Agency Revenue



    110,598



    130,406



    235,253



    356,126

    Non-Agency Revenue



    28,104



    3,548



    73,076



    9,300

    Total Medicare Revenue



    138,702



    133,954



    308,329



    365,426

    Other Revenue

















    Non-Encompass BPO Services Revenue



    2,528



    23,119



    9,322



    58,056

    Other Revenue



    1,549



    1,581



    8,286



    5,765

    Total Other Revenue



    4,077



    24,700



    17,608



    63,821

    Total Net Revenue



    $         142,779



    $         158,654



    $         325,937



    $         429,247





    (1)

    Commissions revenue excludes commissions generated through the Company's non-Encompass BPO Services as well as from the sale of individual and family plan insurance products.

     

    The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):





    Three months ended Jun. 30,



    Six months ended Jun. 30,

    (in thousands)



    2023



    2022



    2023



    2022

    Marketing and advertising



    $                164



    $                215



    $                230



    $                656

    Customer care and enrollment



    725



    624



    1,329



    1,255

    Technology



    921



    627



    1,688



    1,609

    General and administrative



    8,310



    12,791



    13,457



    15,892

    Total share-based compensation expense



    $           10,120



    $           14,257



    $           16,704



    $           19,412

     

    The following table sets forth our balance sheets for the periods indicated (unaudited):

    (in thousands, except per share amounts)



    Jun. 30, 2023



    Dec. 31, 2022

    Assets









    Current assets:









    Cash and cash equivalents



    $           25,364



    $           16,464

    Accounts receivable, net of allowance for doubtful accounts of $734 in 2023 and $89 in 2022



    35,984



    4,703

    Commissions receivable - current



    294,319



    335,796

    Prepaid expense and other current assets



    12,431



    57,593

    Total current assets



    368,098



    414,556

    Commissions receivable - non-current



    617,243



    695,637

    Operating lease ROU asset



    17,215



    21,483

    Other long-term assets



    2,243



    1,721

    Property, equipment, and capitalized software, net



    23,870



    25,282

    Intangible assets, net



    453,583



    500,611

    Total assets



    $      1,482,252



    $      1,659,290

    Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity









    Current liabilities:









    Accounts payable



    $             8,704



    $           15,148

    Accrued liabilities



    49,802



    53,334

    Commissions payable - current



    103,953



    122,023

    Short-term operating lease liability



    6,765



    8,974

    Deferred revenue



    27,721



    50,594

    Current portion of long-term debt



    —



    5,270

    Other current liabilities



    13,313



    10,112

    Total current liabilities



    210,258



    265,455

    Non-current liabilities:









    Commissions payable - non-current



    220,652



    253,118

    Long-term operating lease liability



    35,234



    38,367

    Long-term debt, net of current portion



    496,224



    504,810

    Other non-current liabilities



    9,823



    5,839

    Total non-current liabilities



    761,933



    802,134

    Commitments and Contingencies









    Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares

    issued and outstanding at June 30, 2023 and December 31, 2022. Liquidation preference of $50.9 million at

    June 30, 2023 and December 31, 2022.



    49,302



    49,302

    Stockholders' equity:









    Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 9,499 and 8,963 shares

    issued; 9,418 and 8,950 shares outstanding at June 30, 2023 and December 31, 2022, respectively.



    1



    1

    Class B common stock – $0.0001 par value; 616,022 and 616,259 shares authorized; 12,818 and

    13,054 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively.



    1



    1

    Preferred stock – $0.0001 par value; 20,000 shares authorized (including 50 shares of Series A

    redeemable convertible preferred stock authorized and 200 shares of Series A-1 convertible preferred

    stock authorized); 50 shares issued and outstanding at June 30, 2023 and December 31, 2022.



    —



    —

    Series A-1 convertible preferred stock— $0.0001 par value; 200 shares authorized; no shares issued

    and outstanding at June 30, 2023 and December 31, 2022.



    —



    —

    Treasury stock – at cost; 81 and 13 shares of Class A common stock at June 30, 2023 and December

    31, 2022, respectively.



    (1,051)



    (345)

    Additional paid-in capital



    646,232



    626,269

    Accumulated other comprehensive income (loss)



    (125)



    (144)

    Accumulated deficit



    (395,144)



    (357,023)

    Total stockholders' equity attributable to GoHealth, Inc.



    249,914



    268,759

    Non-controlling interests



    210,845



    273,640

    Total stockholders' equity



    460,759



    542,399

    Total liabilities, redeemable convertible preferred stock and stockholders' equity



    $      1,482,252



    $      1,659,290

     

    The following table sets forth the net cash provided by (used in) operating activities for the periods presented (unaudited):

    Net cash provided by (used in) operating activities



    Six months ended Jun. 30,



    Trailing Twelve Months ended Jun. 30,



    2023



    2022



    2023



    2022



    $                  31,340



    $                    6,377



    $                  85,867



    $           (260,379)

     

    In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations. Below are the most relevant business and operating metrics, besides EBITDA and Adjusted EBITDA, for our single operating and reportable segment.

    The following tables set forth the reconciliations of Medicare Revenue per Submission, Operating Expense per Submission, and Gross Margin per Submission to Sales per Submission, Cost Per Submission, and Adjusted Gross Margin per Submission for the periods indicated (unaudited):





    Three months ended Jun. 30,



    Six months ended Jun. 30,





    2023



    2022



    2023



    2022

    Sales per Submission

















    Medicare Revenue per Submission



    $              852



    $              865



    $              819



    $              879

    Lookback Adjustments reported during the indicated periods1



    —



    20



    —



    14

    Sales per Submission



    $              852



    $              885



    $              819



    $              893



















    Cost per Submission

















    Operating Expense per Submission



    $           1,202



    $           1,677



    $           1,022



    $           1,337

    Indirect operating expenses2



    (458)



    (629)



    (346)



    (392)

    Lookback Adjustments reported during the indicated periods1



    —



    6



    —



    4

    Exit of non-Encompass BPO Services



    (14)



    (127)



    (21)



    (114)

    Share-based compensation expense



    (5)



    (5)



    (4)



    (5)

    Cost per Submission



    $              725



    $              922



    $              651



    $              830



















    Gross Margin per Submission3



    $            (350)



    $           (812)



    $           (203)



    $            (458)

    Adjusted Gross Margin per Submission4



    $              127



    $             (37)



    $              168



    $                63





    (1)

    Excludes the impact of Lookback Adjustments on non-Encompass BPO Services.

    (2)

    Indirect operating expenses include technology, general and administrative, amortization of intangible assets and operating lease impairment charges.

    (3)

    Medicare Revenue per Submission less Operating Expense per Submission.

    (4)

    Sales per Submission less Cost per Submission.

     

    The following table presents the number of Submissions for the periods presented (unaudited):

    Submissions



    Three months ended Jun. 30,











    2023



    2022



    Change



    % Change



    $                162,837



    154,893



    $                    7,944



    5.1 %



















    Six months ended Jun. 30,











    2023



    2022



    Change



    % Change



    $                376,482



    415,559



    $                (39,077)



    (9.4) %

     

    The following table presents the Sales per Submission for the period presented (unaudited):

    Sales Per Submission



    Three months ended Jun. 30,











    2023



    2022



    $ Change



    % Change



    $                       852



    $                       885



    $                       (33)



    (3.7) %



















    Six months ended Jun. 30,











    2023



    2022



    $ Change



    % Change



    $                       819



    $                       893



    $                       (74)



    (8.3) %

     

    The following are our Sales/Cost of Submission, Cost of Submission (in thousands) and Cost Per Submission for the three and six months ended June 30, 2023 and 2022 (unaudited):





    Three months ended Jun. 30,



    Six months ended Jun. 30,





    2023



    2022



    2023



    2022

    Sales/Cost of Submission



    1.2



    1.0



    1.3



    1.1

    Cost of Submission



    $                118,080



    $                142,853



    $      245,250



    $                345,103

    Cost per Submission



    $                       725



    $                       922



    $             651



    $                       830

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gohealth-reports-second-quarter-2023-results-301897536.html

    SOURCE GoHealth, Inc.

    Get the next $GOCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOCO

    DatePrice TargetRatingAnalyst
    11/19/2025Outperform → Mkt Perform
    William Blair
    4/1/2022$1.50Underperform
    Credit Suisse
    3/3/2022$10.00 → $2.00Outperform → Sector Perform
    RBC Capital
    3/2/2022Buy → Hold
    Truist
    3/2/2022$2.00Buy → Hold
    Truist Securities
    1/7/2022$6.00 → $3.00Neutral → Underperform
    Credit Suisse
    1/5/2022$7.50 → $3.50Buy → Underperform
    B of A Securities
    11/15/2021$7.00 → $6.00Neutral
    Credit Suisse
    More analyst ratings

    $GOCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoHealth Prioritizes Retention, Quality, and Strategic Flexibility as Medicare Advantage Market Rationalizes; Reports Third Quarter 2025 Results

    CHICAGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and nine months ended September 30, 2025. The Company navigated a materially different Medicare Advantage environment by intentionally reducing Medicare Advantage volume, conserving liquidity, and preserving the core capabilities required to scale when market conditions stabilize. Based on our analysis, health plans continue to emphasize margin integrity, renewal stability, and long-term member value over raw enrollment growth. GoHealth anticipated this shi

    11/13/25 7:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth to Announce Third Quarter 2025 Results on November 13, 2025

    CHICAGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its third quarter 2025 financial results on the morning of November 13, 2025. Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Brendan Shanahan, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand lis

    11/11/25 9:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth Helps Medicare Consumers Navigate Another Disruptive Annual Enrollment Period (AEP) With Personalized Guidance

    CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- As millions of Medicare beneficiaries face another disruptive Medicare Annual Enrollment Period (AEP), GoHealth, Inc. (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, continues to leverage its proprietary technology to ensure ‘peace of mind' for consumers navigating a complex and volatile market. GoHealth's PlanFit technology enables licensed insurance agents to offer comprehensive, personalized guidance and improve the plan comparison and shopping experience for the consumer. Across the Medicare industry, about 2 million Medicare Advantage beneficiaries are estimated to be affected by plan exits,

    10/14/25 2:30:00 PM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoHealth downgraded by William Blair

    William Blair downgraded GoHealth from Outperform to Mkt Perform

    11/19/25 8:54:30 AM ET
    $GOCO
    Specialty Insurers
    Finance

    Credit Suisse resumed coverage on GoHealth with a new price target

    Credit Suisse resumed coverage of GoHealth with a rating of Underperform and set a new price target of $1.50

    4/1/22 7:10:27 AM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth downgraded by RBC Capital with a new price target

    RBC Capital downgraded GoHealth from Outperform to Sector Perform and set a new price target of $2.00 from $10.00 previously

    3/3/22 4:36:13 AM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    SEC Filings

    View All

    SEC Form EFFECT filed by GoHealth Inc.

    EFFECT - GoHealth, Inc. (0001808220) (Filer)

    12/29/25 12:15:10 AM ET
    $GOCO
    Specialty Insurers
    Finance

    SEC Form S-3 filed by GoHealth Inc.

    S-3 - GoHealth, Inc. (0001808220) (Filer)

    12/16/25 5:04:08 PM ET
    $GOCO
    Specialty Insurers
    Finance

    SEC Form EFFECT filed by GoHealth Inc.

    EFFECT - GoHealth, Inc. (0001808220) (Filer)

    12/2/25 12:15:29 AM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kotte Vijay bought $100,275 worth of shares (7,500 units at $13.37), increasing direct ownership by 1% to 653,630 units (SEC Form 4)

    4 - GoHealth, Inc. (0001808220) (Issuer)

    11/15/23 10:10:34 AM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Shanahan Brendan Richard covered exercise/tax liability with 12,725 shares, decreasing direct ownership by 5% to 237,275 units (SEC Form 4)

    4 - GoHealth, Inc. (0001808220) (Issuer)

    11/4/25 3:15:09 PM ET
    $GOCO
    Specialty Insurers
    Finance

    Chief Operating Officer Hargis Mike covered exercise/tax liability with 5,545 shares, decreasing direct ownership by 2% to 324,993 units (SEC Form 4)

    4 - GoHealth, Inc. (0001808220) (Issuer)

    9/16/25 4:46:40 PM ET
    $GOCO
    Specialty Insurers
    Finance

    SEC Form 3 filed by new insider Weinsten Mark Robert

    3 - GoHealth, Inc. (0001808220) (Issuer)

    9/3/25 9:50:04 AM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

    SC 13D/A - GoHealth, Inc. (0001808220) (Subject)

    8/25/23 6:15:20 AM ET
    $GOCO
    Specialty Insurers
    Finance

    SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

    SC 13D/A - GoHealth, Inc. (0001808220) (Subject)

    8/25/23 6:03:57 AM ET
    $GOCO
    Specialty Insurers
    Finance

    SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

    SC 13D/A - GoHealth, Inc. (0001808220) (Subject)

    5/19/23 6:08:49 AM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    Leadership Updates

    Live Leadership Updates

    View All

    Brendan Shanahan Appointed Chief Financial Officer of GoHealth, Bringing Decades of Leadership in Healthcare and Financial Strategy

    CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, today announced the appointment of Brendan Shanahan as Chief Financial Officer (CFO), effective October 14, following a comprehensive search process. Mr. Shanahan, a seasoned executive with over 30 years of financial leadership experience and over 20 years of expertise in the Medicare Advantage space, will oversee GoHealth's financial strategy and operations, contributing to the company's profitable growth and innovation efforts. "Brendan's extensive expertise in financial strategy, M&A, operational leadership, and deep knowledge of t

    10/10/24 9:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth Appoints Vance Johnston as Chief Financial Officer

    CHICAGO, Dec. 6, 2021 /PRNewswire/ -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced today that Vance Johnston will join the Company as Chief Financial Officer (CFO) on December 7, 2021.  As previously announced, Travis Matthiesen, the Company's current CFO, will transition to the role of Chief Transformation Officer and will work closely with Johnston to ensure a smooth transition. "We are very pleased that Vance will be joining the GoHealth executive team as CFO," said Clint Jones, co-fou

    12/6/21 4:05:00 PM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth Appoints Dr. Paul Hain, M.D. as Chief Medical Officer

    CHICAGO, Dec. 1, 2020 /PRNewswire/ -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace, announced today that Dr. Paul Hain, M.D. has joined the company as Chief Medical Officer. In this newly created role, Dr. Hain will work side-by-side with GoHealth's growing TeleCare team, directly building clinical functions within the recently developed Encompass Platform, a digital health solution that provides strategic value to GoHealth members and enterprise partners. Dr. Hain will focus on key member touchpoints including care management and navigation, provider and value-based care engagement, pharmacy engagement, health risk assessments, social determinant of he

    12/1/20 8:06:00 AM ET
    $GOCO
    Specialty Insurers
    Finance

    $GOCO
    Financials

    Live finance-specific insights

    View All

    GoHealth Prioritizes Retention, Quality, and Strategic Flexibility as Medicare Advantage Market Rationalizes; Reports Third Quarter 2025 Results

    CHICAGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and nine months ended September 30, 2025. The Company navigated a materially different Medicare Advantage environment by intentionally reducing Medicare Advantage volume, conserving liquidity, and preserving the core capabilities required to scale when market conditions stabilize. Based on our analysis, health plans continue to emphasize margin integrity, renewal stability, and long-term member value over raw enrollment growth. GoHealth anticipated this shi

    11/13/25 7:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth to Announce Third Quarter 2025 Results on November 13, 2025

    CHICAGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its third quarter 2025 financial results on the morning of November 13, 2025. Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Brendan Shanahan, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand lis

    11/11/25 9:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance

    GoHealth Announces Strategic Capital and Governance Actions to Support Long-Term Value Creation and Reports Second Quarter 2025 Results

    CHICAGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced the execution of strategic capital and governance actions that are expected to significantly enhance its financial flexibility and long-term positioning along with its financial results for the three and six months ended June 30, 2025. Strategic Capital and Governance Actions Secured new senior secured superpriority term loan facility, including $80.0 million in new-money term loans and $35.0 million in roll-up loans, to support working capital and stra

    8/7/25 7:00:00 AM ET
    $GOCO
    Specialty Insurers
    Finance